Training and Resources
KEYTRUDA® (pembrolizumab) in endometrial cancer resources
Prescribing Information [External link]
KEYTRUDA, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults.
KEYTRUDA (pembrolizumab)
KEYNOTE-868 (NRG-GY018) clinical data presentation
Prescribing Information [External link]
For more information about KEYTRUDA plus chemotherapy in endometrial cancer, explore our product page
Prescribing Information [External link]
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
KEYTRUDA (pembrolizumab) and lenvatinib KEYNOTE-775 clinical data presentation
Prescribing Information [External link]
For more information about KEYTRUDA plus lenvatinib in endometrial cancer, explore our product page
Prescribing Information [External link]
Please refer to the SmPC for further information before making any prescribing decisions.
KEYTRUDA® (pembrolizumab) in cervical cancer resources
Prescribing Information [External link]
KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) ≥1.
KEYTRUDA® (pembrolizumab) KEYNOTE-826 clinical data presentation
Prescribing Information [External link]
For more information about KEYTRUDA in cervical cancer explore our product page
Prescribing Information [External link]
Please refer to the SmPC for further information before making any prescribing decisions.
Patient education and support materials
Please be aware you should not direct patients to this website. You should download the diary on their behalf and share it with them as appropriate.
KEYTRUDA® (pembrolizumab) in combination with chemotherapy patient diary
Prescribing Information [External link]
To order printed versions of these diaries to your place of work, please contact:
msdukoncology@msd.com
Prescribing Information [External link]
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
